Tell me more about the trial

This trial aims to see how safe the investigational medication is and how it works to slow or stop cancer growth when compared with standard treatments. The standard treatments used in this trial are 3 different approved chemotherapies for breast cancer.

The trial is for people whose breast cancer:

•  is human epidermal growth factor receptor 2-low (HER2-low)
  • HER2-low means that cancer cells have a small amount of a protein called human epidermal growth factor receptor 2 (HER2).
• is hormone receptor positive (HR+)
  • HR+ means that cancer cells can attach to the hormones estrogen and progesterone.
• did not get better with previous treatment or has spread to other parts of the body.

How long you will be in the DYNASTY-Breast02 Trial depends on how the cancer you have responds to the trial medication. You will need to stop taking the trial medication if the cancer gets worse or you have serious side effects.

Here is a bit more information for you to know:

• The investigational medication will be given as an intravenous (IV) infusion into a vein.
• The chemotherapies will be given either as an IV infusion or as a tablet taken by mouth.
• If you are given the investigational medication, you will receive it once every 3 weeks.
• This trial will include about 532 people worldwide.